LARIMAR THERAPEUTICS, INC. Debt Securities, Available-for-sale, Allowance for Credit Loss
LARIMAR THERAPEUTICS, INC. (LRMR) had Debt Securities, Available-for-sale, Allowance for Credit Loss of $0 as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Credit Losses
us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2026-03-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2025-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2025-09-30: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
| Period end | Debt Securities, Available-for-sale, Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-04 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-04 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 |
| 2025-03-31 | $0.00 10-Q · filed 2025-04-30 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-19 |
| 2024-09-30 | $0.00 10-Q · filed 2024-10-30 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-24 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-14 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-10 |
| 2020-12-31 | $0.00 10-K · filed 2021-03-04 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-12 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-14 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |